Brought to you by 
Stromedix raises $25mm in Series B for fibrosis programs
08 May 2008
Executive Summary
Stromedix (fibrotic disease therapeutics) has completed a $25mm Series B round led by New Leaf Venture Partners along with other new investors Bessemer Venture Partners and Red Abbey Venture Partners. Returning backers Atlas Venture and Frazier Healthcare Ventures also participated in the financing. New Leaf's Ron Hunt and Bessemer's Chris Gabrieli will join Stromedix's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Stromedix raises $25mm in Series B for fibrosis programs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice